ArticleTherapeutic advances in psychopharmacology2026
Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system.
Article in Therapeutic advances in psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In February 2025, the FDA ended the mandatory Risk Evaluation and Mitigation Strategy requirements for clozapine. Korea continues mandatory hematologic testing under the Clozapine Patient Monitoring System (CPMS), yet no nationwide updates have been reported since 2006. Objectives: This study aimed to provide contemporary real-world evidence on the incidence, timing, and clinical outcomes of clozapine-associated neutropenia and agranulocytosis in Korea, and to evaluate adherence to monitoring regulations, to inform potential revision of the national CPMS. Design: A retrospective, multicenter cohort study was conducted using anonymized electronic medical records from two Korean tertiary hospitals between 2000 and 2023. Methods: Patients with schizophrenia spectrum disorders who had newly initiated clozapine were included. Absolute neutrophil count (ANC) data were used to identify neutropenia (ANC < 1500/μL), moderate neutropenia (<1000/μL), and agranulocytosis (<500/μL). Chart review determined causality for agranulocytosis. Monitoring adherence was assessed based on the proportion of ANC tests conducted within recommended intervals. Results: Among 2417 newly initiated patients (from 3364 total users), neutropenia occurred in 9.7%. Of these, 47.4% occurred within 18 weeks, and none who continued treatment progressed to agranulocytosis. Patients with neutropenia had lower baseline ANC than those without. Moderate neutropenia occurred in 1.7% and showed similar clinical patterns, most events being transient. Ten cases of agranulocytosis were identified, of which four (0.17%) were clozapine-related. All appeared abruptly within 5 weeks of initiation without preceding neutropenia or low baseline ANC, and recovered after discontinuation. Monitoring adherence was suboptimal: during the first 18 weeks, adherence to ⩽10-day interval was 73.7%, while 8.7% patients had no ANC tests; adherence after 1 year fell below 50%. Conclusion: Neutropenia is relatively common but usually low-risk, whereas clozapine-induced agranulocytosis is rare, abrupt, and confined to the early period. These findings suggest reconsideration of current hematological monitoring regulations regarding clozapine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.